Show simple item record

dc.contributor.advisorUddin, Md. Jasim
dc.contributor.authorMd.Minhaj-Ul-Alam
dc.date.accessioned2021-10-21T05:51:31Z
dc.date.available2021-10-21T05:51:31Z
dc.date.copyright2021
dc.date.issued2021-06
dc.identifier.otherID 17346058
dc.identifier.urihttp://hdl.handle.net/10361/15509
dc.descriptionThis thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.en_US
dc.descriptionCataloged from PDF version of thesis report.
dc.descriptionIncludes bibliographical references (pages 24-49).
dc.description.abstractCovid-19, a worldwide disease, affects millions of people. As of now, there is no effective technique to avoid infection. This outbreak emphasizes pandemic preparedness. Contrary to popular belief, the Covid-19 vaccination is delivered via transdermal microneedling rather than parenteral administration. Dissolving microneedles are best suited to eliciting the necessary immunity and antibody against Covid-19. It also allows for delayed and sustained antigen delivery, making it an effective pharmacological approach for immunizing. Why Transdermal microneedle vaccine administration allows for individualized distribution and reduced vaccine waste, while parenteral vaccine delivery is intrusive, requires cold chain storage, and does not allow for customized delivery. The challenges of clinical translation and sterilization are simply overcome by greater research. Vaccines are also avoided due to needle phobia, which is eliminated with painless transdermal microneedle delivery. Transdermal microneedle delivery may help us reach our aim of vaccinating as many individuals as possible.en_US
dc.description.statementofresponsibilityMd.Minhaj-Ul-Alam
dc.format.extent49 pages
dc.language.isoenen_US
dc.publisherBrac Universityen_US
dc.rightsBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.
dc.subjectFormulationen_US
dc.subjectTransdermal microneedleen_US
dc.subjectCovid-19 vaccineen_US
dc.subject.lcshCOVID-19 (Disease)
dc.subject.lcshVaccines
dc.subject.lcshTransdermal medication
dc.titleCovid-19 vaccine for transdermal delivery: formulation consideration and microneedle accessionen_US
dc.typeThesisen_US
dc.contributor.departmentDepartment of Pharmacy, Brac University
dc.description.degreeB. Pharmacy


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record